NEW YORK (GenomeWeb News) – Signal Genetics today said that Arkansas Blue Cross Blue Shield will cover the company's molecular assay for multiple myeloma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.